TILS.L Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 saus. 1970 @ 03:00):

Stats
Dzisiejszy wolumen	297 128
Średni wolumen	184 066
Kapitalizacja rynkowa	0.00
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-0.110
ATR14	£0 (0.00%)

Tiziana Life Sciences PLC Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Tiziana Life Sciences PLC Finanse

Annual	2020
Przychody:	£0.00
Zysk brutto:	£0.00 (0.00 %)
EPS:	£-0.191

FY	2020
Przychody:	£0.00
Zysk brutto:	£0.00 (0.00 %)
EPS:	£-0.191

FY	2019
Przychody:	£0.00
Zysk brutto:	£0.00 (0.00 %)
EPS:	£-0.0540

FY	2018
Przychody:	£0.00
Zysk brutto:	£0.00 (0.00 %)
EPS:	£-0.0940

Financial Reports:

No articles found.

Tiziana Life Sciences PLC

Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops Anti IL-6r (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat hospitalized COVID-19 patients with severe respiratory symptoms; and StemPrintER, a multi-gene signature assay intended for use in patients diagnosed with estrogen-receptor positive ER+/HER2 negative breast cancers. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.